The price of Cabaletta Bio Inc (NASDAQ: CABA) closed at $16.18 in the last session, down -4.99% from day before closing price of $17.03. On the day, 1019096 shares were traded.
Ratios:
We take a closer look at CABA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.29 and its Current Ratio is at 15.29. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on February 05, 2024, initiated with a Buy rating and assigned the stock a target price of $36.
On November 29, 2023, William Blair started tracking the stock assigning a Outperform rating and target price of $38.
On October 24, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $40.Cantor Fitzgerald initiated its Overweight rating on October 24, 2023, with a $40 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 19 ’24 when Binder Gwendolyn sold 11,000 shares for $19.59 per share. The transaction valued at 215,439 led to the insider holds 20,000 shares of the business.
Binder Gwendolyn sold 11,000 shares of CABA for $240,789 on Dec 19 ’23. The insider now owns 20,000 shares after completing the transaction at $21.89 per share. On Nov 20 ’23, another insider, Binder Gwendolyn, who serves as the insider of the company, sold 11,000 shares for $17.82 each. As a result, the insider received 196,014 and left with 20,000 shares of the company.
Stock Price History:
Over the past 52 weeks, CABA has reached a high of $26.35, while it has fallen to a 52-week low of $7.69.
Shares Statistics:
A total of 47.82M shares are outstanding, with a floating share count of 34.77M. Insiders hold about 18.86% of the company’s shares, while institutions hold 96.32% stake in the company.
Earnings Estimates
The company has Alibaba Group Holding Limited analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $61.75, with high estimates of $0.71 and low estimates of $16.18.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Consumer Cyclical.
